PET radiotracer design for monitoring targeted immunotherapy

April 7, 2017
Comparison of (A) Cu-64-DOTA-HACPD1, (B) Cu-64-NOTA-HAC-PD1, and (C) Cu-64-NOTA-HACA-PD1 ImmunoPET images acquired at 1h p.i. (~1.85 MBq/10 μg/200 μl) of NSG mice bearing dual subcutaneous tumors in shoulders (right = hPD-L1+; left = hPD-L1-). Panels left to right show representative coronal and axial cross sections of CT, PET, and merged PET/CT images with maximum intensity projection (MIP). White dashed line, coronal image, demarcation of axial cross-section; White dashed line, axial image, tumor boundary. SG, salivary gland; T+, hPD-L1 positive tumor; T-, hPD-L1 negative tumor; L, lung; Li, liver; K, kidney; B, bladder; H, heart. Scale bars represent 1 percent (blue) - 6 percent (red) ID/g. Tumor uptake was quantified using ROI analysis (right panel) without partial volume correction. Error bars represent SD. ns, not significant; *p<0.05, **p<0.01, ***p<0.001, student's T test. Credit: Sam Gambhir, MD, PhD, Stanford University

In an article published in the April issue of The Journal of Nuclear Medicine, researchers at Stanford University in California provide a template for assessing new positron emission tomography (PET) radiotracers that can accurately identify molecules in cancer cells that prevent the immune system from attacking the cancer.

A drug that blocks a cancer's inhibitory checkpoint molecules is called an and this form of immunotherapy has emerged as a promising cancer treatment approach. However, the lack of imaging tools to assess immune checkpoint expression has been a major barrier to predicting and monitoring response to a clinical checkpoint blockade.

"Because immunotherapies for cancer are expanding, methods to optimize them for an individual patient through are needed," explains Sam Gambhir, MD, PhD, at Stanford University. "Using animal models, this study shows the development of several new engineered PET tracers that can help image the immune system in action and be used to monitor checkpoint inhibitor therapy."

The study assessed practical immunoPET radiotracer design modifications and their effects onhuman PD-L1 immune checkpoint imaging. The researchers sought to optimize engineering design parameters including chelate, glycosylation, and radiometal to develop a non-invasive molecular imaging tool for eventual monitoring of clinical checkpoint blockade.

Gambhir points out, "This research will ultimately allow for translation to human imaging of the tracer that worked best in animal models. An effective immunoPET tracer will help patients receiving checkpoint inhibitor immunotherapy get optimal treatment and have the best chance for fighting their cancer."

Molecular imaging is playing an increasingly integral role in immunotherapy and personalized medicine. Looking ahead, Gambhir envisions "a lot more use of PET/CT or PET/MR imaging for patients undergoing immunotherapy." He adds, "This and related research will also help us develop other imaging approaches for understanding the immune system in action."

Explore further: Nanoparticle treatment could improve immunotherapy against cancer

More information: "Practical ImmunoPET radiotracer design considerations for human immune checkpoint imaging", Journal of Nuclear Medicine (2017). DOI: 10.2967/jnumed.116.17765

Related Stories

Nanoparticle treatment could improve immunotherapy against cancer

April 3, 2017
Researchers at the University of North Carolina Lineberger Comprehensive Cancer Center have discovered a potential novel strategy for improving drugs that unleash the immune system against cancer—by binding two compounds ...

New immunotherapy combination shows promise for patients with advanced melanoma

April 5, 2017
Treatment with a combination of ipilimumab (Yervoy) and Coxsackievirus A21 (CVA21; Cavatak) led to durable responses in a number of patients with advanced melanoma, including some whose melanoma had progressed despite prior ...

Adding the IDO-pathway inhibitor indoximod to pembrolizumab improved the melanoma response rate

April 5, 2017
Adding the investigational immunotherapy indoximod to the FDA-approved immunotherapy pembrolizumab (Keytruda) increased the proportion of patients with advanced melanoma who responded to treatment compared with previously ...

Researchers show how a targeted drug overcomes suppressive immune cells

November 9, 2016
A Ludwig Cancer Research study shows that an experimental drug currently in clinical trials can reverse the effects of troublesome cells that prevent the body's immune system from attacking tumors. The researchers also establish ...

Combination immunotherapy effective for advanced prostate cancer

March 9, 2017
Advanced prostate cancer resistant to castration therapy appears to respond well to a combination of immune checkpoint blockades and treatments that target certain immune-busting cells commonly associated with poor patient ...

Immune checkpoint blockade improves antitumor vaccine response in mouse glioblastoma model

July 7, 2016
Glioblastoma has an extremely poor prognosis, and there is a critical need for new therapies to treat the disease. Immunotherapy helps the immune system destroy cancer cells, and recent clinical evaluation of an immune cell-based ...

Recommended for you

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

Computer program finds new uses for old drugs

November 16, 2017
Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, ...

Pharmacoscopy improves therapy for relapsed blood cancer in a first clinical trial

November 16, 2017
Researchers at CeMM and the Medical University of Vienna presented a preliminary report in The Lancet Hematology on the clinical impact of an integrated ex vivo approach called pharmacoscopy. The procedures measure single-cell ...

Wider sampling of tumor tissues may guide drug choice, improve outcomes

November 15, 2017
A new study focused on describing genetic variations within a primary tumor, differences between the primary and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the blood stream could help ...

A new strategy for prevention of liver cancer development

November 14, 2017
Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly in the United Stated. In late stages of the malignancy, there are no effective ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.